We kick off our #ESMO26 coverage with the primary analysis of the phase 3 DeLLphi-305 trial presented by @sands_jacob

Back to meeting Original

Back to meeting

Medthority· @Medthority · X·2026-10-25 00:00· 14 hours agoScore70

DELLPHI-305

Body

We kick off our #ESMO26 coverage with the primary analysis of the phase 3 DeLLphi-305 trial presented by @sands_jacob

#LungCancer #Oncology #SCLC #OncTwitter #MedEd #MedX

26 views · 0 likes · 0 reposts · 0 replies

Conference abstracts

LBA3matched by Presidential Symposium I

Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial

https://esmocongress.esmo.org

Source: Medthority · x.com